Home » OXXON THERAPEUTICS LICENSES RIGHTS TO XENOVA'S DISC-HSV AND DISC-GM-CSF VECTOR TECHNOLOGIES
OXXON THERAPEUTICS LICENSES RIGHTS TO XENOVA'S DISC-HSV AND DISC-GM-CSF VECTOR TECHNOLOGIES
Oxxon Therapeutics has licensed exclusive worldwide rights to Xenova Group's DISC-HSV and DISC-GM-CSF vector platforms for use in developing products for certain major cancers and chronic infectious diseases. DISC-GM-CSF, used as a stand-alone product, has been tested in a number of oncology indications including a dose-ranging Phase I trial for melanoma.
Yahoo News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May